PMID- 11606390
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20131121
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 61
IP  - 20
DP  - 2001 Oct 15
TI  - Combined intratumoral injection of bone marrow-derived dendritic cells and 
      systemic chemotherapy to treat pre-existing murine tumors.
PG  - 7530-5
AB  - Dendritic cells (DCs) are attractive candidates for innovative cancer 
      immunotherapy by virtue of their potential to function as professional 
      antigen-presenting cells for initiating cellular immune responses. In this study, 
      we evaluated a possible synergy of conventional chemotherapy together with 
      intratumoral injection of syngeneic bone marrow-derived DCs for the treatment of 
      preexisting tumors. Using murine CT26 colon adenocarcinoma cells (parental or 
      modified to express beta-galactosidase as a model tumor antigen) to produce s.c. 
      tumors in syngeneic BALB/c mice, the data demonstrate that direct injections of 
      DCs at the tumor site result in partial eradication of established tumors. 
      Strikingly, the addition of systemic chemotherapy (cyclophosphamide) combined 
      with local intratumoral injection of DCs led to complete tumor regression in the 
      treated animals. The tumor-free mice were able to resist a repeat challenge with 
      the same tumor, suggesting that the animals had acquired long term antitumor 
      immunity. Supporting evidence for the paradigm of systemic chemotherapy and 
      intratumoral administration of DCs was obtained using melanoma B16 syngeneic 
      tumor treated with Adriamycin plus DCs. These novel findings raise the 
      possibility of using this potent strategy of combined intratumoral injections of 
      DCs and systemic chemotherapy for cancer treatment.
FAU - Tong, Y
AU  - Tong Y
AD  - Division of Pulmonary and Critical Care Medicine, Weill Medical College of 
      Cornell University, New York, New York 10021, USA.
FAU - Song, W
AU  - Song W
FAU - Crystal, R G
AU  - Crystal RG
LA  - eng
GR  - R01 CA75192/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antineoplastic Agents)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Bone Marrow Cells/cytology/immunology
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/*pharmacology
MH  - Dendritic Cells/*immunology
MH  - Doxorubicin/*pharmacology
MH  - Female
MH  - Immunologic Memory
MH  - Immunotherapy, Adoptive/*methods
MH  - Injections, Intralesional
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/drug therapy/immunology/*therapy
MH  - T-Lymphocytes, Cytotoxic/immunology
EDAT- 2001/10/19 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/19 10:00
PHST- 2001/10/19 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/19 10:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2001 Oct 15;61(20):7530-5.